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Abstract
Introduction: Efforts were made to improve management of coronary disease as the fast-track system to the
Coronary Unit. We aim to analyse case-fatality rates by acute coronary syndrome in Portugal from 2000 to 2016,
mainly the impact of the fast-track system and the proportion of patients that activate the fast-track system.
Methods: We analysed monthly acute coronary syndrome case-fatality before and after the implementation of the fast-
track system in 2007. Impact of the system was assessed through regression models for interrupted time-series. We
calculated annual proportion of fast-track system admissions.
Results: After 2007 case-fatality by acute coronary syndrome decreased (b¼1.27, p-value< 0.01). The estimates
obtained for ST Elevation Myocardial Infarction suggest a reduction of nearly 86 monthly deaths prevented after 2007.
The highest percentage of patients admitted through the fast-track system was 35%.
Conclusions: Our results suggest fast-track system may have contributed to a decline in acute coronary syndrome
case-fatality. However, more than half of patients were not admitted through the system. This should encourage health
authorities to make efforts to ensure compliance.
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Introduction
Cardiovascular disease (CVD) is the leading cause of
death in Europe and the most common cause of death
in Portugal.1 It is estimated that by 2030, ischaemic
heart disease will be the third leading cause of death
worldwide.2 Despite recent decreases in mortality rates
in many countries, CVD is still responsible for almost
half of all deaths in Europe,3 constituting a major
public health challenge in Western Europe.4
Although coronary heart disease (CHD) mortality
rates have been declining since the 1980s in Portugal,
more steeply after the mid-1990s, particularly among
women5 and across the EU, there is evidence of a con-
sistent pattern of recent plateaus in CHD mortali-
ty rates.6
The observed reduction in CDV mortality in the last
decades, albeit at a low rate, is the result of a set of
changes from efforts made by most European countries
in disease prevention, tackling mainly risk factors, and
of the improvements in disease management
and treatment.
Particularly in Portugal, several improvements in
CHD management have been made, with improve-
ments in the availability of drug treatments and,
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more importantly, in the easiest and fastest access to
reperfusion and revascularisation interventions.6
The evidence-based effectiveness of the health poli-
cies is increasing, and we have realised that a variety of
policy- and practice-related measures will be necessary
to effectively reduce CVD prevalence and mortality as
well as to promote changes in the healthcare system.
Thus, it is important to assess the relative contribu-
tion of these underlying factors to the observed decline
in CHD mortality in different settings to develop future
health policies.
In Portugal, several policies have been implemented
that could impact mortality rates by acute coronary
syndrome (ACS), from polices more focusing on dis-
ease prevention to policies more directly targeting mor-
tality, such as the recent implementation of a fast-track
system (FTS) with direct admission to the Coronary
Care Unit (CCU). There is, therefore, a growing con-
sensus about the unmet need for health policy
impact analysis.7
As time is crucial in ACS, time is muscle, it is essen-
tial to create measures that can help reducing the time
to treatment, thus reducing mortality and morbidity
associated with ACS.
Although the FTS was implemented in Portugal to
reduce the time to CCU, recent studies have shown a
small proportion of patients activating the system.
Therefore, we analysed the impact of a FTS to CCU
(via verde coronária in Portuguese) in case-fatality
rates by ACS in Portugal from 2000 to 2016, even
when a small proportion of patients activated
the system.
Material and methods
Data
Data were obtained from the Diagnosis Related Group
National Database, which collects data from all admis-
sions into Portuguese public hospitals (Mainland
Portugal), storing data on primary diagnosis and
some demographic variables such as sex and age, as
well as the geographic region of the admission.8
Approval to access data was obtained previously
from the Minister of Health Office and the
Portuguese Society of Cardiology.
All admission cases from 2002 to 2016 were
extracted, and only participants aged 20 and over,
with primary diagnosis of ACS coded in ICD 9 (inter-
national classification of disease, 9th revision) as
410.00-410.xx to identify admission diagnosis of acute
myocardial infarction (AMI) and 4130 codes, to iden-
tify unstable angina (UA), were analysed.
A second population dataset was used from the
National Registry of Acute Coronary Syndrome
(NRACS),9 and for our study, we extracted all data
from 2002 to 2015. This dataset was used to obtain
the proportion of ACS patients that were admitted
into the hospital through the FTS. This proportion
was computed by using the total number of ST
Elevation Myocardial Infarction (STEMI) patients in
the denominator and the number of STEMI patients
that activated the FTS system in the numerator. We
focused on STEMI patients once the system was
mainly directed to STEMI as these are frequently
more symptomatic10 and the fast track is a patient-
initiated process, thus patients with Non-ST
Elevation Myocardial Infarction (NSTEMI) might be
less likely to activate the FTS.
This dataset has the advantage of being integrated
into the Euro Heart Survey platform and, consequent-
ly, uses the Cardiology Audit and Registration Data
Standards system, which ensures that credible and
comparable information is collected in several
European countries over time as they use standardised
information, both in terms of the definition and coding
of variables and in the form of data measurement and
collection. As the data are validated and standardised,
this allows for the possibility of applying and validating
analyses in other larger populations, thus obtaining
more robust results.11
The FTS was implemented in all regions of Portugal
in 2007, providing seven years of data before the imple-
mentation of the regulation (January 2000–December
2007) and nine years of data after the regulation was
implemented (January 2008–December 2016).
The unit of analysis was monthly deaths by ACS.
Fast track to CCU. The FTS was implemented in
Portugal with the goal of creating a priority system
and facilitated access to clinical, therapeutic, and com-
plementary diagnostic resources. Direct admission into
the CCU is essential not only to improve accessibility,
but also to allow a more effective treatment, since the
time between the onset of symptoms and treatment is,
in the case of AMI, vital for the reduction of morbidity
and mortality.
The system is initiated by the patients when calling
the emergency number (112). The National Institute of
Medical Emergency (INEM) initiates the diagnosis and
treatment earlier while referring the person to a hospi-
tal unit specialising in ACS treatment.12
Once when the INEM is activated (by patients
through the emergency number) they have the capacity
to prematurely, as soon they are in contact with the
patient, do an electrocardiogram, and along with the
symptoms assessment make a diagnosis. If the diagno-
sis is established it is then decided, along with the
Urgent Care Counselling Centre (CODU), on the
pre-hospital treatment as well as on the referral to
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hospitals, increasing the likelihood of therapeutic suc-
cess. The CODU contacts the nearest hospital unit with
a catheterisation laboratory, in order to take the nec-
essary steps for the expedited admission and treatment
of the patient.13 Once the CODU is contacted, the
nearest catheterisation laboratory is prepared for the
patients and a team of specialists are ready to receive
them, thus the time from symptom onset to revascular-
isation is minimised.
The system was first implemented as a pilot project
in the Algarve region of the country in 2002, but only
by 2007, it was implemented as a policy throughout
Mainland Portugal.14
Statistical analysis. The main outcome in our study was
monthly case-fatality rate, later stratified by age and
sex, which were obtained using data from ACS patients
admitted into public hospitals in the country. All miss-
ing data were removed from all the analysis.
The ACS case-fatality rate was computed for each
month by using the total of patients admitted into
public hospital as the denominator and the number
of ACS deaths as the numerator.
The impact of the breakpoint estimated for the
impact of the fast-track implementation on ACS case-
fatality rate was assessed through multiple linear
regression models, using standard methods for inter-
rupted time-series.15,16 We included one dichotomous
variable that accounted for the main effect on ACS
case-fatality rate of the estimated breakpoint and an
interaction between the breakpoint estimated and the
time, to evaluate changes over time following
the breakpoint.
The model was implemented to test whether there
was a significant change in the number of ACS case-
fatality rates and if the fast track had any impact.
A month indicator covariable was introduced to
adjust for seasonality in the outcome admissions.
All analyses were stratified by demographic varia-
bles such as sex and age, and further stratified by
type of AMI, i.e. STEMI versus NSTEMI, removing
UA patients. Age was grouped into two catego-
ries,< 65 and  65 years old. Autocorrelation between
month estimates was incorporated adequately into the
model, with the presence of short-term autocorrelation,
applying a first-order autoregressive – AR(1) – struc-
ture to the residuals.
As not all hospitals in mainland Portugal have the
capacity to adopt the FTS because of a lack of human
and technical resources, we also compared case fatality
trends for hospitals with the FTS in place versus hos-
pitals with no such system. Generalised least squares
regression was applied, with a dichotomous variable
distinguishing hospitals with the FTS from those
without such a system and a month indicator to
account for seasonal variations.
We also calculated the total time from symptom
onset to first medical contact (FMC). The time was
then analysed through a generalised linear model,
assuming a linear behaviour of time, using as covari-
ates a dichotomous variable before and after the fast-
track implementation, demographic variables (sex and
age) and risk factors (smoking, hypertension, diabetes,
dyslipidaemia, obesity). The variable representing the
use of the FTS was a ‘yes’ or ‘no’ categorical variable,
which included fast-track admission versus self-
transportation and non-medical ambulance.
Although we are aware that there might be differ-
ences in case-fatality rates according to the day of the
week, weekend versus week day, we did not adjust for
that in our models since there are studies pointing to a
steady reduction in CVD for both weekends and week-
days.17 There are also studies showing that after
accounting for mode of arrival at hospital, there are
no differences in case-fatality rates between weekdays
or weekends.18
Using data from the NRACS, we computed the
monthly proportion of patients with ACS, namely
STEMI diagnosis, that were admitted into the hospital
through the FTS, divided by the total number of
patients admitted into the hospitals.
Statistical significance was assessed through p-
values, assuming< 5% as significant, and 95% confi-
dence intervals were calculated for each of the regres-
sion coefficients.
Models were fitted in R version 2.3.2 software.
Results
A total of 20,849 in-hospital deaths by ACS were reg-
istered in the country (Mainland Portugal) from 2000
to 2016, out of a total of 203,040 ACS admissions.
We assessed monthly case-fatality rates by ACS for
the period of 2000–2016, and our results show a decline
in the number of registered deaths for the period stud-
ied. After the year of the implementation of the FTS in
2007, the year used as a breakpoint in the model cre-
ated (Figure 1), there was a steep decrease in case-
fatality rate, although there were no significant differ-
ences from the rate observed in the period before, thus
the rate of the decline has remained steady throughout
the last 15 years.
There was a significant change in level, i.e. a signif-
icant drop in ACS case-fatality rate (b¼1.268,
p-value: <0.01) after the FTS implementation, repre-
senting an abrupt intervention effect.15
Although the change in trend was not significant, i.e.
there was not a significant decrease in the slope after
the fast-track implementation, the fact that there was a
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significant change in level denotes a clear change in
ACS case-fatality rate after 2007; on the other hand,
it also points out to the fact that the rates after have
remained fairly similar to the rates of decline observed
before the FTS.
We stratified the ACS case-fatality rate by sex, and
the trends observed for the pre-system implementation
and the post-system implementation were similar for
both men and women (Figure 2, Table 1). For both
men and women, there was a steep decrease after the
system was implemented; however, as for the overall
rate, the decreasing trends remained fairly steady.
Although the immediate decrease was similar for men
and women, the reduction in ACS case-fatality rate was
Figure 1. Longitudinal trends for case-fatality rate by ACS (percentage) from January 2000 to December 2016. The vertical line
marks the year 2007 for the full implementation of the FTS in the entire country. ACS: acute coronary syndrome.
Figure 2. Stratified longitudinal trends for case-fatality rate by ACS (percentage) from January 2000 to December 2016. The vertical
line marks the year 2007 for the full implementation of the FTS in the entire country. (a) Longitudinal trends for males, (b) longitudinal
trends for females, (c) longitudinal trends for patients under 65, and (d) longitudinal trends for patients over 65. AMI: acute myocardial
infarction; NSTEMI: Non-ST Elevation Myocardial Infarction; STEMI: ST Elevation Myocardial Infarction.
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more marked in women (b¼1.45, p-value¼ 0.01)
than in men (b¼ 1.06, p-value¼ 0.01) (Figure 2,
Table 1).
Interestingly, the results for age stratification
showed that for people under 65, there was an increas-
ing trend in case fatality (b¼ 0.01, p-value¼ 0.01),
although the change in trend was significant, it was in
fact a minor increase, less than 0.05%.
However, for patients aged 65 and over, the case
fatality trend was also significant (b¼ 0.02, p-val-
ue¼ 0.02). For younger participants, although the
increase trend was significant, it was a minor increase
of less than 0.05%.
The seasonal pattern observed was consistent with
that reported elsewhere,19 with higher rates of admis-
sion over winter and lower rates during the summer.
In addition, when studying the further stratified results
by STEMI versus NSTEMI and removing patients with
UA (Figure 3), there was an immediate significant
decrease for STEMI case-fatality rate (Table 1) in
2007; no significant changes in case fatality trends were
observed for NSTEMI after 2007. The estimates obtained
for STEMI case-fatality rate suggest a reduction of nearly
86 monthly deaths prevented after 2007 (Table 1).
Analysis of the NRACS data allowed us to assess
the actual proportion of patients that activated the
FTS over time. Although the proportion of fast-track
admission has been increasing over time it has only
reached a maximum value of 38% in 2016, it has
been a slow increase (Figure 4).
Furthermore, we compared the ACS case-fatality
rate between hospitals with a FTS implemented and
Table 1. Results of segmented linear regression analyses to detect association between fast-track system and monthly case-fatality
rate ACS and multivariate regression analysis between time from symptom onset and several predictors.
b (CI) t-value p-value
Impact of the fast-track system on case-fatality rate by ACS
Overalla
Fast track implemented 1.27 (2.10; 0.436) 2.99 < 0.01
Fast track implementeda time interaction 0.005 (0.011; 0.020) 0.58 0.565
Malea
Fast track implemented 1.064 (1.869; 0.258) 2.59 0.01
Fast track implementeda time interaction 0.006 (0.009;0.021) 0.74 0.46
Femalea
Fast track implemented 1.453 (2.555; 0.352) 2.59 0.01
Fast track implementeda time interaction 0.009 (0.011;0.029) 0.89 0.37
Age< 65a
Fast track implemented 0.184 (0.302; 0.669) 0.74 0.46
Fast track implementeda time interaction 0.011 (0.003; 0.019) 2.60 0.01
Age  65a
Fast track implemented 0.348 (1.413; 0.716) 0.64 0.52
Fast track implementeda time interaction 0.023 (0.004; 0.041) 2.44 0.02
Impact of the fast-track system on case-fatality rate stratified by type of AMI
STEMIa
Fast track implemented 1.038(1.830; 0.246) 2.57 0.01
Fast track implementeda time interaction 0.010(0.025;0.004) 1.39 0.17
NSTEMIa
Fast track implemented 0.229(0.735;1.194) 0.47 0.64
Fast track implementeda time interaction 0.019(0.003:1.629) 0.09 0.46
Time from symptom onset to first medical contact
Fast track (yes) 47.14 (60.48; 33.79) 6.92 < 0.01
Age 1.60 (1.28; 1.92) 9.73 < 0.01
Sex (male) 15.28 (6.91; 23.66) 3.58 < 0.01
Smoker (yes) 17.58 (26.92; 8.23) 3.69 < 0.01
Hypertension (yes) 3.88 (4.12; 11.88) 0.95 0.34
Diabetes (yes) 15.72 (7.45; 23.98) 3.73 < 0.01
Dyslipidaemia (yes) 2.84 (10.22; 4.54) 0.76 0.45
Obesity (yes) 9.02 (0.12; 17.92) 1.99 0.05
ACS: acute coronary syndrome; AMI: acute myocardial infarction; CI: confidence interval; NSTEMI: Non-ST Elevation Myocardial Infarction; STEMI: ST
Elevation Myocardial Infarction.
b represents the coefficients of the regression.
aAll regression models were adjusted for seasonal effects.
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hospitals with no such system, as a proxy to compare
case-fatality rates, although we acknowledge the fact
that hospitals with the FTS can still admit patients
that reach the hospital by any other way of transpor-
tation. Our results indicate a significantly lower case-
fatality rate for hospitals with the FTS implemented
(b¼0.67, p-value< 0.01; Figure 5).
Mean time from symptom onset to FMC was also
analysed. For patients admitted through the FTS, the
mean time from symptom onset to FMC was
224.20 min, approximately 3 h, while for patients that
were not admitted through this system, mean time from
symptom onset to FMC was 354 min, approximately
6 h (Figure 6). When assessing the results from the
multivariate regression (Table 1), time from symptom
onset to FMC was significantly lower for participants
admitted through the FTS, up to around 50 min less.
Analysis of the demographics and risk factor covariates
used in the model denoted that older people and
women, as well as patients with diabetes and obesity,
had longer delays. Surprisingly, smokers had lower
times from symptom onset to FMC.
Discussion
Trends in mortality by AMI have been decreasing
steadily in Europe. In Portugal, mortality by ACS
has been studied up to 2008 and showed around 3760
fewer deaths in 2008 compared to the expected number
if the rates observed in 1995 had persisted.5 More
recently, a set of health policies tackling not only dis-
ease prevention, but also decrease in mortality, were
implemented in the country, namely the FTS in 2007,
the smoking ban in 2009, and a salt reduction regula-
tion in mid-2010. Although in our study, we focused on
the impact of the FTS on case-fatality rates, all these
policies can affect CVD mortality.
Although CHD mortality rates in Portugal
decreased by more than 25% between 1995 and 2008,
we found a significant decrease immediately after the
implementation of the FTS up to 2016. Although we
cannot attribute this directly to the FTS, the reductions
found up to 2008 were attributable to better care and
treatments, explaining half of the overall decline in
CHD deaths. Furthermore, by 2008, the fast-track
system was already implemented, and also there was
an increase in the number of centres with a catheter-
isation laboratory. Also, by 2008, approximately 42%
of the decrease could be attributed to an improvement
in major risk factors5; therefore, regulations such as the
Figure 3. Longitudinal trends for case-fatality rate by ACS (percentage) from January 2000 to December 2016 for STEMI versus
NSTEMI patients. The vertical line marks the year 2007 for the full implementation of the FTS in the entire country.
Figure 4. Percentage of annual STEMI patients admitted
through the FTS.
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smoking ban and mandatory salt reduction probably
had a greater influence on mortality rates.
Our study also shows there was a steep decrease in
case-fatality rate the year of the implementation of the
fast track; however, the rate of decline observed after
that was similar to the years previous to the policy.
This is most likely to lower proportion of patients acti-
vating the system. On the other hand, there were no
major changes in prescriptions for pharmacological
treatments specifically for the year 200720 that could
explain the decrease observed in case-fatality rate
after this year.
Figure 5. Comparison of longitudinal case fatality trends between hospitals with FTS versus hospitals without the FTS.
Figure 6. Time from symptom to FMC between patients that activated the FTS and patients who did not activate it. FMC: first
medical contact.
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The stratified results for STEMI versus NSTEMI
showed that the significant decrease after 2007 was
only observed for STEMI patients, this was expected
as the FTS is focused mainly for these patients. The
total prevented monthly deaths was around 86 deaths,
although this number is not as high as other studied,
namely a recent meta-analysis that showed reductions
up to 30–40% in hospital mortality after the implemen-
tation of the FTS.21 However, by 2016 only a total of
38% of the STEMI patients have activated the system,
thus more than half of the patients are not beneficiating
from the fast-track policy.
We found similar decreasing case-fatality rates for
men and women, which has previously been observed
in other studies where the rate of decrease in CHD
mortality appeared to be stable across both sexes.6
Surprisingly, our results for age stratification were
not consistent with the overall case-fatality rate. Either
for the youngest or older patients, we observed no
immediate change in case-fatality rate after the FTS
was implemented. For both groups, there were signifi-
cant changes in trend; however, the trends observed
were increasing. The prevalence of obesity and there-
fore diabetes22 is in fact increasing in the country,
which can be attenuating the reductions for the youn-
ger groups. This fact has also been observed in other
studies6,23 where the increase of obesity led to lower
decrements of mortality for the younger groups. A sim-
ilar pattern was observed for the older group, which
has already been found in other datasets and indicates
that older persons benefit the least from the decline in
CVD mortality.23 Other studies have also reported a
persistently high case-fatality rate among the elderly.24
Furthermore, when we compared ACS case-fatality
rates between hospitals with a FTS implemented and
hospitals without such a system, the rates were signif-
icantly different, and lower case-fatality rates were
observed for hospitals that had the FTS. Although
the trends were decreasing for both groups, hospitals
with versus hospitals without the system, the decrease
was more accentuated in the group with the FTS. This
kind of system allows earlier diagnosis and direct com-
munication between the ambulance team and the CCU,
bypassing the ER, thus minimising time to treatment,
which leads to better prognosis and, consequently, less
case-fatality rates.
Previous studies have shown that minimising time to
treatment using the FTS can directly lead to diminished
case-fatality rates.25,26
The observed mean time (3 h), even for patients
admitted through the FTS, was longer than the recom-
mended time,27 which is 1.5–2 h after symptom onset.
These types of results have already been reported in
other studies where the average delay time from symp-
tom onset to FMC remained at around 2 h and did not
decrease despite multiple public education
campaigns.28
A decrease of 50 min was observed for patients
admitted through the FTS when compared to patients
not admitted through this system, and similar reduc-
tions in time have been observed in other studies.29
The variables affecting symptom onset to FMC were
not surprising, as most were found in other studies and
associated with longer delays.
Although there is clear evidence, in our study as well
as in previous studies, of the effectiveness of a FTS,
more than half of the patients are not using this
system. As this is a patient-initiated process, even
when proven to be the best way of admission if patients
and the community at risk do not have either sufficient
health literacy to acknowledge their symptoms or the
process is not widespread enough, the impacts of these
health policies will not reach full capacity.
Moreover, Portugal was one of the countries to par-
ticipate in a global initiative that aims to improve the
delivery of facilities by increasing timely access to pri-
mary percutaneous coronary intervention, thus reduc-
ing mortality and morbidity in STEMI patients. The
project was responsible for the launch of a national
public campaign to raise public awareness of the symp-
toms of MI, among other objectives.
The OCDE recently revealed that the use of primary
PCI increased dramatically in countries that had been
participating in the ‘Stent for Life’ initiative. In fact,
one year after implementation of the initiative in
Portugal, a positive impact was observed, with greater
use of the 112 emergency call service and a smaller
number of patients arriving by their own means at
local hospitals without PCI facilities.30 This suggests
that health campaigns, such as the ‘stent for life’ cam-
paign, can have an impact on the health community
and the general community.
Limitations
Nonetheless, we recognise some limitations of the
study. Like in any ecological study, it is not possible
to directly prove the association between the implemen-
tation of the FTS and the reduction in case-fatality rate
by ACS. In Portugal, considerable efforts have been
made to improve patient care, thereby increasing
patient awareness to symptoms and improving patient
health. The implementation of a national smoking
ban31 and of a salt reduction regulation32 might have
affected the findings in our study, making this decrease
in case-fatality rate a multifactor effect rather than a
‘one approach effect’. In addition, there are more fac-
tors, besides the public health campaigns mentioned
above, that could impact case-fatality rates by ACS,
such as novel pharmacological therapeutics, as well as
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change from a CK-based assay to a troponin assay, use
of higher sensitivity troponin.
The fact that the decrease in case-fatality rate was
observed right after 2007 supports our theory that FTS
played a major role in this decrease, once the smoke
ban and salt regulation were implemented after this
year, also, pharmacological therapeutics have been
steadily improving with no particular innovation in
2007 that helped justify the decrease in case-fatality
rate by ACS.
In addition, we compared case-fatality rates between
hospitals with a FTS and hospitals without such as
system. Although we could not distinguish the patients
admitted through this system, we found significant dif-
ferences in case-fatality rates between hospitals with
versus hospitals without this system.
One of the strengths of our study is the use of two
well validated and standardised databases, allowing for
an easy comparison with other international studies,
mainly those developed in other European countries.
As well as the availability of information on gender and
age, this allowed us to assess the robustness of our
findings among different subgroups. Also, the time-
series method is preferred over the simpler pre- and
post-proportion comparison method, because it does
not take the pre-intervention trend into account and
also allows to correct for autocorrelation.33
Conclusions
Our study extends the existing literature on the patterns
of ACS mortality over time and allows assessing
whether the current strategies to reduce mortality by
ACS, namely policy interventions, are successful.
Furthermore, our study suggests that policies such as
the FTS are related to a decline in ACS case fatality,
supporting the importance of this policy type in achiev-
ing health gains.
Considering that CHD is the number one cause of
death in the Western world and as such constitutes an
immense public health problem,34 even a small
improvement in treatment and an increase in patient
awareness can have important clinical, economic, and
social gains. On the other hand, our study showed that
although the proportion of patients activating the FTS
is increasing, more than half of the patients are not
using the system. This highlights the importance of
continuous education to the general community in
terms of guideline adherence, regarding the importance
of rapid reperfusion therapy, which can directly affect
case-fatality rates. Although it is a learning curve, since
the FTS is a patient-initiated process and thus,
although the system is available, not all patients
resort to it, as more evidence arises for the effectiveness
of this type of policy, more investment should be
applied into the education of the population.
Our results encourage legislators and public health
authorities to make efforts to ensure compliance with
the FTS, leading to a patient’s timely access to treat-
ment and allowing better prognosis, thus reducing
mortality and morbidity by ACS.
Contributorship
DA – perfomed all statistical analysis and drafted the manu-
script and is the guarantor of all data used.
CA and FP – reviwed and ammemened when necesary.
PS – Was responsible for giving inputs on the methoidolog-
ical desing and revising the manuscript.
Acknowledgements
The authors thank the investigators of the NRACS,
Sociedade Portuguesa de Cardiologia.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of
this article.
Ethical approval
The data used in the study were obtained with authorisation
of the Portuguese Cardiology Society and the Directorate
General of Health.
Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
Guarantor
DA.
References
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